CD19 Enrichment: Targeting B Cell Immunotherapy with Precision
Key Biomarker Isolation for CAR-T & Hematological Diagnostics
Isolating and profiling CD19+ B cells under clinical-grade parameters to power advanced cellular therapies, autoimmune diagnostics, and lymphoma research.
CD19 is a transmembrane glycoprotein expressed almost exclusively on B cells throughout their development—except on plasma cells. It acts as a co-receptor with the B cell receptor (BCR) and plays a crucial role in B cell activation, proliferation, and differentiation.
Due to its lineage-specific expression and stable presence on malignant B cells, CD19 serves as a reliable biomarker and therapeutic target.
Why is CD19 Important?
B-cell Acute Lymphoblastic Leukemia
CD19 serves as an essential tumor biomarker for monitoring and targeting B-ALL clonal cells.
Non-Hodgkin Lymphoma
Ubiquitous expression on NHL cells makes it a perfect target for therapeutic monoclonal antibodies.
Chronic Lymphocytic Leukemia
Indicates specific B-cell maturity stages and acts as a marker for tracking CLL diagnostic progression.
What is CD19 Enrichment?
CD19 enrichment is the process of isolating CD19-positive B cells from blood or bone marrow samples using immunomagnetic separation (MACS) or high-speed flow cytometry (FACS). This is essential for both research and clinical applications, such as CAR-T cell development and disease monitoring.
Applications of CD19 Enrichment
- ✓CAR-T Cell Therapy: Targeting CD19 with CAR-T cells for treating relapsed/refractory B-cell malignancies.
- ✓B Cell Functional Assays: Studying signalling, antibody production, or cytokine expression profiles.
- ✓Autoimmune Disease Research: Examining CD19+ B cells in diseases like lupus and rheumatoid arthritis.
- ✓Transplantation Studies: CD19 monitoring in bone marrow transplantation for graft purity and relapse detection.
Genestac's CD19 Enrichment Services
Genestac Therapeutics provides industry-leading CD19+ B cell enrichment services for translational research and immunotherapy workflows:
High-purity magnetic bead-based or FACS sorting
Viability and phenotypic confirmation (CD19, CD20, CD27)
Compatible with downstream culture, sequencing, or reprogramming
Fast turnaround time and scalable volumes
CD19 in CAR-T Cell Therapy: A Game Changer
CD19 has revolutionized cancer treatment through CAR-T cell therapy (e.g., Tisagenlecleucel, Axicabtagene ciloleucel). Enriched CD19-positive targets are essential for validating CAR constructs and conducting preclinical cytotoxicity assays.
CD19 is a pivotal biomarker in modern immunology and oncology. Whether for CAR-T development or fundamental research on B cell function, Genestac's CD19 enrichment solutions provide the specificity and reliability you need for impactful outcomes.
Frequently Asked Questions (FAQs)
Is CD19 expressed on all B cells?
CD19 is expressed on almost all stages of B-cell development, from early pre-B cells to mature B cells. However, it is down-regulated and lost when B cells undergo terminal differentiation into mature antibody-producing plasma cells.
Can CD19 be used as a target in autoimmune disease?
Yes. B cells play a key role in producing autoantibodies in autoimmune diseases. Therapies targeting CD19+ cells (such as monoclonal antibodies or CD19-targeted CAR-T cells) are being actively researched and applied to treat severe, refractory autoimmune conditions like systemic lupus erythematosus (SLE).
Access CD19 Enrichment Solutions
Consult our experts at Genestac Therapeutics to design high-yield CD19+ sorting and enrichment protocols.
